SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is drawing attention amid renewed concerns about its heavy debt burden, high borrowing costs and HSBCs bearish assessment of its ability to fund growth. Traders are split between viewing the decline as an overdone move that could fuel a rebound and warning that financing risks could keep pressure on the AI infrastructure provider.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after its CEOs anniversary message prompted renewed speculation about a potential buyout, alongside anticipation for the final analysis of its Phase 3 REGAL leukemia trial, which requires 80 events and was last reported at 78. Traders disagree on whether the message and prolonged trial timeline signal favorable data or a deal; neither a buyout nor a trial outcome has been confirmed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on fears of Middle East supply disruptions, including reported attacks on shipping and energy infrastructure and heightened Iran-US tensions. Traders are divided between bulls focused on geopolitical supply risks and bears who see peace-deal headlines, disputed reports, or a normalization of flows unwinding the oil premium.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, as investors weigh financing risks and warnings that some providers may not survive; traders are frustrated that IREN has lagged peers and debate whether the weakness is justified. Some point to the co-CEOs comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while others remain concerned about sector-wide risk and continued selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound toward the $83,000 area has fueled talk of a breakout and possible short squeeze, with bullish traders pointing to resilient buying. Others call the move a temporary bounce and stress that Bitcoin needs to hold key levels above $82,000$83,000 to sustain momentum.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows, amid concerns about Trumps standing ahead of the midterms and Truth Socials declining appeal, dominates discussion. The community is broadly bearish, citing weak business fundamentals and continued selling, while a few traders see scope for a short-term bounce.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods steep selloff and continued weakness dominate discussion, with traders pointing to analyst caution and a risk-off market ahead of earnings. Bears see more downside, while bulls argue the pullback is a buying opportunity and watch for support to hold.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians reported Q3 outlook increase and reaffirmation of its 2026 outlook, alongside Carnivals strong results lifting cruise shares, are driving renewed interest. Bulls point to resilient bookings and heavy short interest as reasons for optimism, while others remain cautious about fuel costs, debt, and NCLHs lagging performance versus peers; squeeze talk is speculative.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.Iran deal are driving a sharp, volatile SPY rebound, with traders linking the reports and falling oil prices to the move. The community is split between chasing calls and viewing the rally as a fake-news pump that could fade, citing the lack of official confirmation and conflicting denials.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance and widespread frustration with managements shift toward external acquisitions and pipeline investment, which critics fear could add debt and dilution. Bulls point to Orladeyos revenue and upcoming Netherton and Navenibart data, while bearish traders question whether those prospects can restore confidence.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom...

Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document

Equity

The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.


Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months...

Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial

Truist Financial raised shares of Solid Biosciences to a "strong-buy" rating in a research note on Monday...

Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Solid Biosciences from a "hold" rating to a "sell" rating in a report on Sunday...

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the stock...

Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month High  - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Hits New 12-Month High - What's Next...

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - Here's Why

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9% - What's Next...

Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

Solid Biosciences (NASDAQ:SLDB) Trading 6.4% Higher - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Shares Up 6.4% - Here's What Happened...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Neutral Sentiment

<ul class="summary-bullets"><li>FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.</li><li>The documents show that reviewers raised concerns over changes made to the statistical analysis plan for Capricor’s Phase 3 Hope-3 trial.</li><li>Capricor said the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.</li></ul>Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).However, the company responded by stating that the FDA’s review was based on an unsigned, incomplete, and obsolete internal draft.&nbsp;“Our results are governed by the final analysis plan, SAP version 3.0, which was finalized prior to unblinding. It is critical to understand that the post-hoc analyses in the FDA’s briefing materials rely on SAP version 1.1, an unsigned, incomplete internal draft which became obsolete with the addition of cohort B and did not include content specifically requested by FDA,” said CEO Linda Marbán.&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> also recorded its biggest ever single-day slide. It is currently at its lowest levels since December 2025.<h2 class="st-heading-2">Reviewers Say Deramiocel Study Fails to Meet Primary, Secondary Efficacy Endpoints</h2>The FDA on Monday&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated">released</a> briefing documents ahead of a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee. In the documents, FDA reviewers said the study failed to meet its pre-specified primary and secondary efficacy endpoints, finding no statistically significant difference between Deramiocel and placebo after 12 months.Duchenne muscular dystrophy is a rare inherited disorder that mainly affects boys, causing progressive muscle weakness, and there are no FDA-approved treatments specifically for the heart disease that often develops as the condition worsens.The advisory committee will review Capricor’s Biologics License Application (BLA) for the drug before the FDA makes its final decision by the Prescription Drug User Fee Act (PDUFA) target date of Aug. 22, 2026. A PDUFA date is the deadline by which the FDA decides whether to approve a drug for marketing in the United States.<h2 class="st-heading-2">Reviewers Question Changes To Trial Analysis</h2>The documents show that reviewers raised concerns over changes made to the statistical analysis plan (SAP) for Capricor’s Phase 3 Hope-3 trial. In December 2025, Capricor stated that its Phase 3 Hope-3 trial met its primary endpoint of improving upper-limb function and its key secondary endpoint of preserving heart function, with both showing statistically significant results.However, the reviewers said multiple changes were made after the randomized portion of the study, including revisions to the primary and secondary endpoints, analytical methods, and data imputation strategy. They also noted that the final SAP was not submitted for review before the company’s BLA and that the study’s pre-specified procedures for making such changes were not followed.&nbsp;The documents also highlighted a higher rate of hypersensitivity reactions in patients treated with Deramiocel, which it said may have increased the risk of functional unblinding during the trial.<h2 class="st-heading-2">What’s Next?</h2>The advisory committee has been recommended to discuss whether data from the Hope-3 and Hope-2 studies show that Deramiocel can slow the decline in heart function in patients with Duchenne muscular dystrophy.The panel will also consider whether the combined results provide enough evidence that the therapy improves upper-limb function and is an effective treatment for the disease.<h2 class="st-heading-2">Retail’s Take On CAPR</h2>Despite the slump, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid a 320% jump in message volumes. CAPR was also among the top trending stocks on the platform at the time of writing.One user said there’s a “60% chance that they will have to redo the Adequate and controlled cardiac primary trial.”<stembedurl>https://stocktwits.com/PB09/message/660074196</stembedurl>However, another user was confident that Capricor will be able to answer whatever questions the committee will have with “proven data and results.”<stembedurl>https://stocktwits.com/Stormfury66/message/660074439</stembedurl>The stock has shed more than 77% so far this year.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fbrx-stock-surges-why-argenx-buying-forte-biosciences/cZZxWT5R7Cr">FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Shares of Capricor Therapeutics (CAPR) tanked more than 67% on Monday after U.S. Food and Drug Administration (FDA) reviewers expressed concerns in briefing documents over whether its lead therapy Deramiocel has shown sufficient effectiveness to treat car

Capricor Therapeutics Inc

Sarepta Therapeutics Inc

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$6.48
Prev Close	$5.92
Open	$5.86
Dividend Yield	0.00%
50-Day Moving Average	$8.33
Beta	2.05
Avg. Volume	1.3M
PE Ratio	-3.10

52-Week High	$11.45
52-Week Low	$3.79
Market Capitalization	$634.77M
EPS (Annual)	-$1.99
Price to Book	1.66
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLDB Fundamentals